Eylea

E579609

Eylea is a widely used injectable drug for treating retinal diseases such as wet age-related macular degeneration by inhibiting vascular endothelial growth factor (VEGF).

Try in SPARQL Jump to: Statements Referenced by

Statements (48)

Predicate Object
instanceOf biologic drug
ophthalmic drug
pharmaceutical drug
hasAdverseEffect cataract
conjunctival hemorrhage
endophthalmitis
eye pain
increased intraocular pressure
intraocular inflammation
retinal detachment
thromboembolic events
vitreous detachment
hasATCCode S01LA05
hasContraindication active intraocular inflammation
hypersensitivity to aflibercept
ocular or periocular infection
hasDosageForm solution for injection
hasGenericName aflibercept
hasIndication diabetic macular edema
macular edema following retinal vein occlusion
myopic choroidal neovascularization
neovascular age-related macular degeneration
wet age-related macular degeneration
hasMechanismOfAction VEGF-A binding
placental growth factor binding
vascular endothelial growth factor inhibitor
hasMolecularType fusion protein
hasPharmacologicalClass angiogenesis inhibitor
recombinant fusion protein
hasRegulatoryApproval European Medicines Agency NERFINISHED
U.S. Food and Drug Administration NERFINISHED
hasRouteOfAdministration intraocular
intravitreal injection
hasTherapeuticArea ophthalmology
retinal vascular disease
hasYearOfFirstApproval 2011
isAdministeredBy ophthalmologist
isAdministeredFrequency every 4 weeks during initial phase
every 8 weeks during maintenance phase
isManufacturedBy Regeneron Pharmaceuticals NERFINISHED
isMarketedBy Bayer NERFINISHED
Regeneron Pharmaceuticals NERFINISHED
isUsedFor prevention of vision loss
reduction of macular edema
treatment of retinal diseases
targets VEGF-A NERFINISHED
VEGF-B NERFINISHED
placental growth factor

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.